{"id":832436,"date":"2025-04-01T12:47:11","date_gmt":"2025-04-01T16:47:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/"},"modified":"2025-04-01T12:47:11","modified_gmt":"2025-04-01T16:47:11","slug":"avidity-biosciences-to-participate-in-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/","title":{"rendered":"Avidity Biosciences to Participate in Upcoming Investor Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 1, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that Avidity management will participate in a fireside chat during the following investor conference:<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg\" title=\"(PRNewsfoto\/Avidity Biosciences, Inc.)\" alt=\"(PRNewsfoto\/Avidity Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<ul type=\"disc\">\n<li>\n          <b>24<sup>th<\/sup> Annual Needham Virtual Healthcare Conference<\/b>\u00a0on <span class=\"xn-chron\">Tuesday, April 8, 2025<\/span>, at <span class=\"xn-chron\">3:00 p.m. ET<\/span><\/li>\n<\/ul>\n<p>Live webcast of the event, up-to-date event details and an archived replay will be available on the &#8220;Events and Presentations&#8221; page in the &#8220;Investors&#8221; section of Avidity&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4395690-1&amp;h=1167881939&amp;u=https%3A%2F%2Faviditybiosciences.investorroom.com%2Fevents-and-presentations&amp;a=https%3A%2F%2Faviditybiosciences.investorroom.com%2Fevents-and-presentations\" target=\"_blank\" rel=\"nofollow\">https:\/\/aviditybiosciences.investorroom.com\/events-and-presentations<\/a>.<\/p>\n<p>\n        <b>About Avidity<\/b>\n      <\/p>\n<p>Avidity Biosciences, Inc.&#8217;s mission is to profoundly improve people&#8217;s lives by delivering a new class of RNA therapeutics &#8211; Antibody Oligonucleotide Conjugates (AOCs\u2122). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in <span class=\"xn-location\">San Diego, CA.<\/span> For more information about our AOC platform, clinical development pipeline and people, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4395690-1&amp;h=2427339129&amp;u=https%3A%2F%2Fwww.aviditybiosciences.com%2F&amp;a=www.aviditybiosciences.com\" target=\"_blank\" rel=\"nofollow\">www.aviditybiosciences.com<\/a>\u00a0and engage with us on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4395690-1&amp;h=2137871185&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Favidity-biosciences-llc%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4395690-1&amp;h=2819826141&amp;u=https%3A%2F%2Fx.com%2Faviditybio&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>.<\/p>\n<p>\n        <b>Investor Contact:<br \/><\/b>Kat Lange<br \/>(619) 837-5014<br \/><a href=\"mailto:investors@aviditybio.com\" target=\"_blank\" rel=\"nofollow\">investors@aviditybio.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA54470&amp;sd=2025-04-01\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/avidity-biosciences-to-participate-in-upcoming-investor-conference-302416463.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/avidity-biosciences-to-participate-in-upcoming-investor-conference-302416463.html<\/a><\/p>\n<p>SOURCE  Avidity Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA54470&amp;Transmission_Id=202504010900PR_NEWS_USPR_____LA54470&amp;DateId=20250401\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , April 1, 2025 \/PRNewswire\/ &#8212;\u00a0Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference\u00a0on Tuesday, April 8, 2025, at 3:00 p.m. ET Live webcast of the event, up-to-date event details and an archived replay will be available on the &#8220;Events and Presentations&#8221; page in the &#8220;Investors&#8221; section of Avidity&#8217;s website at https:\/\/aviditybiosciences.investorroom.com\/events-and-presentations. About Avidity Avidity Biosciences, Inc.&#8217;s mission is to profoundly improve people&#8217;s lives by delivering a new class of RNA therapeutics &#8211; Antibody Oligonucleotide Conjugates (AOCs\u2122). Avidity is revolutionizing the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avidity Biosciences to Participate in Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832436","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avidity Biosciences to Participate in Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avidity Biosciences to Participate in Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , April 1, 2025 \/PRNewswire\/ &#8212;\u00a0Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference\u00a0on Tuesday, April 8, 2025, at 3:00 p.m. ET Live webcast of the event, up-to-date event details and an archived replay will be available on the &#8220;Events and Presentations&#8221; page in the &#8220;Investors&#8221; section of Avidity&#8217;s website at https:\/\/aviditybiosciences.investorroom.com\/events-and-presentations. About Avidity Avidity Biosciences, Inc.&#8217;s mission is to profoundly improve people&#8217;s lives by delivering a new class of RNA therapeutics &#8211; Antibody Oligonucleotide Conjugates (AOCs\u2122). Avidity is revolutionizing the &hellip; Continue reading &quot;Avidity Biosciences to Participate in Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-01T16:47:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avidity Biosciences to Participate in Upcoming Investor Conference\",\"datePublished\":\"2025-04-01T16:47:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/\"},\"wordCount\":302,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/\",\"name\":\"Avidity Biosciences to Participate in Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\",\"datePublished\":\"2025-04-01T16:47:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avidity Biosciences to Participate in Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avidity Biosciences to Participate in Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Avidity Biosciences to Participate in Upcoming Investor Conference - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , April 1, 2025 \/PRNewswire\/ &#8212;\u00a0Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference\u00a0on Tuesday, April 8, 2025, at 3:00 p.m. ET Live webcast of the event, up-to-date event details and an archived replay will be available on the &#8220;Events and Presentations&#8221; page in the &#8220;Investors&#8221; section of Avidity&#8217;s website at https:\/\/aviditybiosciences.investorroom.com\/events-and-presentations. About Avidity Avidity Biosciences, Inc.&#8217;s mission is to profoundly improve people&#8217;s lives by delivering a new class of RNA therapeutics &#8211; Antibody Oligonucleotide Conjugates (AOCs\u2122). Avidity is revolutionizing the &hellip; Continue reading \"Avidity Biosciences to Participate in Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-01T16:47:11+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avidity Biosciences to Participate in Upcoming Investor Conference","datePublished":"2025-04-01T16:47:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/"},"wordCount":302,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/","name":"Avidity Biosciences to Participate in Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","datePublished":"2025-04-01T16:47:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-to-participate-in-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avidity Biosciences to Participate in Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832436"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832436\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}